has not previously been clinically evaluated. We present results from the first-in-human study of U3-1287, a first-in-class HER3-targeting monoclonal antibody. Therapy with U3-1287 was well tolerated and resulted in stable disease and tumor reductions in some patients. Our study lays the foundation for further research into U3-1287 and HER3 inhibition for the treatment of solid tumors.
INTRODUCTION
The human epidermal growth factor receptor (EGFR/HER) family of receptor tyrosine kinases, consisting of HER1 (EGFR), HER2, HER3, and HER4, plays an important role in oncogenesis.
By homodimerizing and heterodimerizing, HER family members activate signaling pathways that are involved in cellular processes, including morphogenesis, proliferation, angiogenesis, and survival.(1-4) A number of tumor types require EGFR or HER2 signaling for growth and survival, (5) (6) (7) prompting the development of various therapeutic agents that target the EGFR and HER2 receptors. Current anti-EGFR and anti-HER2 agents, however, have proven to be effective only in a subset of patients, and initial response is frequently followed by relapse and the development of therapeutic resistance. Recent studies suggest that HER3 upregulation or reactivation is important to the development of resistance to EGFR-and HER2-targeted treatments. (8) (9) (10) (11) Elevated HER3 expression has been detected in many tumor types and is associated with negative clinical prognosis, including shorter relapse-free survival time in breast cancer (12) and shorter overall survival times in lung, ovarian, and colon cancers. (13) (14) (15) (16) HER3 is also overexpressed and occasionally amplified in non-small cell lung cancer (NSCLC), and autocrine loops with its ligands have been documented. (13, (17) (18) (19) (20) While lacking intrinsic kinase activity itself, (21, 22) treated with U3-1287 demonstrate reduced cellular migration, proliferation, and anchorageindependent growth. In addition, U3-1287 and anti-EGFR antibody treatment of EGFR-and HER3-expressing xenografts significantly reduced tumor growth compared with anti-EGFR antibodies alone or with an isotype immunoglobulin (IgG) control in both EGFR wild-type models and resistant models with the T790M EGFR mutation. (27) A phase I, open-label, first-in-human study of single-agent U3-1287 was initiated to assess its safety, tolerability, and pharmacokinetic (PK) profile in patients with advanced solid tumors.
The study was conducted in 2 parts. Part 1 was a dose-escalation, dose-finding study designed to identify the maximum tolerated dose (MTD) by treating successive cohorts with escalating doses and evaluating the incidence of dose-limiting toxicities (DLTs). Part 2 was a doseexpansion phase conducted in patients with advanced malignancies along with an exploratory NSCLC cohort that further evaluated the safety, tolerability, and efficacy of the possible dose levels identified from part 1 PK in the intended phase II population. This report describes results from both parts of this study.
MATERIALS AND METHODS

Patients
For parts 1 and 2, eligible patients had a confirmed diagnosis of an advanced solid tumor that was refractory to standard treatment or for which no standard therapy existed and that was of a type known to express HER3. For part 2, the same eligibility criteria were used, but an exploratory cohort was included in which ≥ 15 of 30 patients enrolled had to have NSCLC.
Patients were not preselected on the basis of RAS or EGFR status. All patients were ≥ 18 years of age, had an Eastern Cooperative Oncology Group performance status of 0 to 2, and a life expectancy of > 3 months. Additional inclusion criteria included controlled hypertension (diastolic ≤ 100 mm Hg; systolic ≤ 140 mm Hg), left ventricular ejection fraction ≥ 50%, 
Study design and dosing
This was a multicenter study conducted in 2 parts. In part 1, dose escalation followed a modified 3 + 3 study design: 3 or 4 patients were enrolled initially in sequential cohorts of 0.3, 1, 3, 6, 9, 14, and 20 mg/kg. U3-1287 was administered as an intravenous (IV) infusion over 60 minutes. After the first IV administration of U3-1287 on day 1, a 21-day observation period occurred for each patient. If no DLTs were observed during the first 21 days, U3-1287 administration began on day 22 and was administered every 14 days. In part 2, the initial dose for dose expansion was determined on the basis of preliminary safety and PK through cohort 5 (9 mg/kg) from the dose-escalation phase of the study. The dose of 9 mg/kg was the first dose 
Tumor response and safety
In part 1 of the study, disease response assessment using modified Response Evaluation Criteria in Solid Tumors (RECIST; 28) was performed at screening, days 35 and 64, and every 8 weeks thereafter. In part 2 of the study, disease response assessment occurred at screening, days 42 and 70, and every 8 weeks thereafter. 2-deoxy-2-( 18 F)fluoro-D-glucose positron emission tomography/computed tomography scans were performed after eligibility was determined and within 14 days prior to the first dose of study drug (baseline) and on day 42 in part 1 (cohorts 3 through 7) and part 2 (all cohorts), once dose levels that might be pharmacodynamically active had been achieved. Metabolic response was assessed as described by Young et al. (29) All adverse events (AEs) were recorded from the time of informed consent until 30 days after the last dose of U3-1287 and were graded according to CTCAE v. electrocardiograms were performed during screening at days 1, 15, 29, 57, and every 4 weeks thereafter. QTc interval was evaluated centrally and corrected for heart rate by the Fridericia's formula (QTcF).
PK evaluation
During part 1, PK evaluation was conducted on all patients on day 1 of treatment (blood samples taken at end of infusion [EOI] , and at 3, 6, 24, and 72 hours after EOI), and on days 7, 14, and 21. Samples were also obtained immediately before the third dose (day 36), at EOI, at 3 and 6 hours after EOI, and on days 37, 39, and 42. Preinfusion and EOI PK samples were also 
Immunogenicity
Blood samples for determining anti-U3-1287 antibodies in serum were collected in part 1 before dosing on day 1 and on day 21, day 64, and every 8 weeks thereafter, as well as during an end-of-study visit. In part 2, blood samples were collected before dosing on days 1, 29, and 57, and then every 8 weeks and at the end-of-study visit. Bremerhaven, Germany) and scored both by absolute copy number and amplification ratio. For IHC, tissue sections were incubated with mouse IgG antihuman HER3 (sc81455, Santa Cruz Biotechnology) and scored as a percentage of positive cells and on a semiquantitative scale using H-scores for total HER3 in the cytoplasm and membrane. Samples were analyzed by a single pathologist who was blinded to clinical outcomes.
RESULTS
Patients
Twenty-six patients were enrolled in part 1, and 31 patients were enrolled in part 2.
Demographics and clinical characteristics are summarized in Table 1 . The most common primary tumor sites were colorectal (50.9%) and NSCLC (35.1%); 17 of the 20 patients with NSCLC were specifically enrolled into the dose-expansion cohorts.
All patients had received chemotherapy, with a median of 5 previous regimens. Forty-one patients (71.9%) received prior EGFR-targeted therapy, of which 3 patients (7.3%) had partial response (PR) as a best response to prior EGFR-targeted treatment, 14 patients (34.1%) had a best response of stable disease (SD), and 16 patients (39.0%) had progressive disease (PD). The best response on prior EGFR-targeted therapy was unknown for 8 patients (19.5%).
All patients received at least 1 dose of U3-1287. Fifty-two patients (91.2%) withdrew from study because of disease progression, 2 patients (3.5%) because of full withdrawal of consent (unrelated to any study-related event), 2 patients (3.5%) because of nonfatal AEs (grade 2 prolonged QTc interval [20 Table 2 ). Based on this limited sample set, it did not appear that any AEs were dose-dependent. U3-1287-related AEs were reported in 26 patients (45.6%) and included fatigue (21.1%), diarrhea (12.3%), nausea (10.5%), decreased appetite (7.0%), and dysgeusia (5.3%). Nearly all drug-related events were grade 1 or 2; only 1 patient (3 mg/kg) had a drug-related AE that was grade ≥ 3 (a nonserious grade 3 event of hyponatremia on day 20 and a nonserious grade 3 event of hypophosphatemia on day 23). Both events were possibly related to study medication. There were no grade 4 or 5 U3-1287-related AEs.
Overall, 6 patients experienced 7 grade ≥ 4 events; none were related to U3-1287. Nineteen patients (33.3%) had a serious AE; none were deemed related to U3-1287. Eight patients discontinued study treatment due to 10 AEs, none of which were judged to be related to treatment with the study drug.
One patient had asymptomatic grade 2 QTcF prolongation, and 3 female patients had asymptomatic QTcF between 450 and 470 ms (normal for females). Analysis of QTcF prolongation as a function of U3-1287 serum concentration showed no concentration dependence (see Supplementary Fig. S1 ).
No DLTs were reported for any of the cohorts during the DLT observation window. Thus, the MTD was not reached and is therefore not lower than the maximum dose administered in this study (20 mg/kg).
Research. 
Pharmacokinetics
PK parameters for dosing cohorts in part 1 are summarized in Table 3 . The C max and AUC of U3-1287 increased more than dose-proportionally across the tested range (0.3-20 mg/kg). PK approached linearity at the higher doses studied (6-20 mg/kg), indicating that saturation of clearance pathways occurs at doses greater than 6 mg/kg. Mean serum t 1/2 was approximately 8 days at doses > 6 mg/kg. Data from PK analysis of part 2 indicate that in patients treated with 9, 14, or 20 mg/kg every 2 weeks (q2w), steady state was achieved after approximately 3 doses. At dose levels ≥ 9 mg/kg, the mean minimum observed serum concentration (C min ) beyond the second dose was at least 10-fold greater than the C min associated with maximal efficacy in mouse xenograft models (90% inhibitory concentration [IC 90 ] ≈ 3 µg/mL; Fig. 1; ref. 30 ).
Owing to this, as well as the simulation of the q2w and every 3 week (q3w) dosing data, the PK profile of U3-1287 supports IV administration at or above 9 mg/kg q2w or q3w.
Immunogenicity
No patient developed human antihuman antibodies (HAHAs) after dosing with U3-1287. One of 26 patients tested during part 1 and 1 of 31 patients tested during part 2 had positive HAHA results before and after exposure to U3-1287, as detected by immunoassay. No neutralizing antibodies were detected at any visit for either patient; therefore, the HAHAs detected were present before dosing and were nonneutralizing.
Efficacy
In the 51 patients evaluable for tumor response, SD at the earliest observation time point was the best single-evaluation response in 50.9% of patients. In part 1, SD was recorded in 1 or more evaluations in 53.8% of patients and maintained for at least 16 weeks in 7.7% of patients.
In part 2, SD was recorded in at least 1 evaluation in 48.4% of patients and maintained for at (Fig. 2) . Twenty-two patients (38.6%) had PD. No patient had complete response or PR per modified RECIST. One patient with NSCLC (20 mg/kg) had tumor shrinkage (26.3% decrease) that approached but did not reach the 30% reduction threshold for PR (Fig. 3) .
The overall metabolic response rate was 3.5%: the previously mentioned NSCLC patient and 1 patient in part 1 (14 mg/kg) had partial metabolic responses. Both patients were nonsmokers who had received prior EGFR-targeted therapy. The first patient previously had a best response of SD while receiving erlotinib-based therapy and, in this study, had SD for 42 weeks. The second patient previously had PD while receiving cetuximab-based therapy and, in this study, was removed for PD after the first tumor assessment post-therapy; however this patient had SD per central review that lasted 32 days. No clear dose response could be discerned given the limited number of responders. Overall in this study, 24.6% of patients had SD, 40.4% had PD, and 31.6% were not evaluable for metabolic tumor response.
Pharmacodynamic and predictive biomarker evaluations
Expression of HER3 was investigated at the gene copy number level by FISH and at the protein expression level by IHC in FFPE tissue sections. Patient subgroups defined using varying cutoff values for gene copy number or amplification ratios, or by protein expression levels, were evaluated for clinical outcome (PD or SD) to identify possible correlations. Results show a trend toward higher proportions of SD patients than PD patients belonging to the subgroups defined by the highest cutoff values for gene copy number or protein expression levels, but this exploratory result requires independent confirmation. Phospho-HER3 was examined as a potential pharmacodynamic and tissue biomarker; however, research using tissue microarrays indicated that the phospho-HER3 epitope is not stable in archived tissue, and fresh tissue could not be examined because patients were not prospectively 
DISCUSSION
This first-in-human study of U3-1287, a first-in-class HER3-targeted fully human monoclonal antibody, supports dosing regimens at a range of 9 to 20 mg/kg U3-1287 q2w or q3w. U3-1287 exhibited a favorable safety profile and preliminary evidence of antitumor activity.
The most frequently reported AEs included fatigue, diarrhea, nausea, and dyspnea. This small patient cohort did not provide clear evidence of a dose-dependent relationship for toxicity. Most incidences of U3-1287-related events were mild to moderate (grades 1 or 2). There were no grade 4 or 5 AEs related to U3-1287, and no treatment discontinuations were attributed to a U3-1287-related AE.
The development of neutralizing antibodies against therapeutic monoclonal antibodies in a patient can lead to the loss of efficacy or to more serious clinical effects. As U3-1287 is a fully human antibody, immunogenicity was not expected to be a concern, and, consistent with this, no neutralizing anti-U3-1287 antibodies were detected in this patient population following exposure to U3-1287. PK results and simulations from q2w dosing suggest that doses 9 mg/kg q3w and above achieve steady state trough levels 10-fold in excess of those corresponding to maximal efficacy in mice. Preclinical experiments showed a correlation between trough concentrations and pharmacodynamics, as assessed by reductions in phospho-HER3 levels (see Supplementary Fig. S2 ). Variation of treatment schedule around a constant dose suggested that trough levels are more important to pharmacodynamics than peak levels in the murine system. However, a number of factors affecting the ability of an antibody to penetrate solid tumors (e.g., variable intervessel distances and high interstitial pressure [31] ) may be less prominent in the smaller tumors of mice. Therefore, the results from murine studies cannot be directly translated into recommended dose levels for humans, and, thus, 9 mg/kg q3w may be viewed as the minimal dose level needed to achieve a significantly higher concentration in humans than is required in murine systems. U3-1287 has demonstrated an acceptable safety profile in doses up to 20 mg/kg q2w; therefore, it is recommended that doses of 9 to 20 mg/kg q2w or q3w be used for collecting further safety, efficacy, and biodistribution data. Ongoing clinical studies are utilizing U3-1287 q3w dosing regimens for enhanced patient convenience. While pharmacodynamic activity could not be effectively assessed in this study to confirm dose selection, 2 independent studies are in progress to refine dose selection: a radiolabeled biodistribution study and a dose-ranging phase I/II study in combination with erlotinib, another HER family inhibitor. -12-3051 that the use of a HER3 inhibitor, such as U3-1287, may prevent or overcome such resistance if used in combination with these agents. The safety and PK profile of U3-1287 monotherapy in this population favors future studies of this agent in combination regimens, particularly with anti-EGFR-and anti-HER2-based therapies used in colorectal, head and neck, and breast cancers. (18,34,35) A phase I/II trial is ongoing to examine U3-1287 (9 or 18 mg/kg q3w) in combination with erlotinib in NSCLC patients.
Acknowledgments
We mg/kg (red symbols), 14 mg/kg (orange symbols), and 20 mg/kg (green symbols). Lower horizontal red line is the trough corresponding to maximal efficacy (IC 90 ) in mice; upper horizontal red line is 10-times this value, the minimal target trough concentration for humans. All 3 doses achieve trough above the human target; higher doses achieve this in all patients sooner, averaging even higher levels.
Fig 2.
SD duration for all subjects with SD per modified RECIST at the earliest observation time point. If a subject discontinued, died, or was lost to follow-up with no documentation of progressive disease, duration of SD was censored at the date of last tumor assessment. 
